- Home
- RGP vs MNPR Comparison
RGP vs MNPR Comparison
Compare RGP & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- MNPR
- Stock Information
- Founded
- RGP 1996
- MNPR 2014
- Country
- RGP United States
- MNPR United States
- Employees
- RGP N/A
- MNPR N/A
- Industry
- RGP Business Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- RGP Consumer Discretionary
- MNPR Health Care
- Exchange
- RGP Nasdaq
- MNPR Nasdaq
- Market Cap
- RGP 178.9M
- MNPR 209.3M
- IPO Year
- RGP 2006
- MNPR 2019
- Fundamental
- Price
- RGP $5.78
- MNPR $33.00
- Analyst Decision
- RGP Sell
- MNPR Strong Buy
- Analyst Count
- RGP 1
- MNPR 6
- Target Price
- RGP $5.00
- MNPR $59.60
- AVG Volume (30 Days)
- RGP 194.7K
- MNPR 54.2K
- Earning Date
- RGP 07-17-2025
- MNPR 08-08-2025
- Dividend Yield
- RGP 5.21%
- MNPR N/A
- EPS Growth
- RGP N/A
- MNPR N/A
- EPS
- RGP N/A
- MNPR N/A
- Revenue
- RGP $560,189,000.00
- MNPR N/A
- Revenue This Year
- RGP N/A
- MNPR N/A
- Revenue Next Year
- RGP $3.85
- MNPR N/A
- P/E Ratio
- RGP N/A
- MNPR N/A
- Revenue Growth
- RGP N/A
- MNPR N/A
- 52 Week Low
- RGP $4.81
- MNPR $1.72
- 52 Week High
- RGP $12.19
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- RGP 52.39
- MNPR 47.53
- Support Level
- RGP $5.23
- MNPR $31.84
- Resistance Level
- RGP $5.54
- MNPR $35.84
- Average True Range (ATR)
- RGP 0.17
- MNPR 1.93
- MACD
- RGP 0.02
- MNPR 0.24
- Stochastic Oscillator
- RGP 52.94
- MNPR 43.68
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.